<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Geron Corporation — News on 6ix</title>
<link>https://6ix.com/company/geron-corporation</link>
<description>Latest news and press releases for Geron Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/geron-corporation" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683576a678dffbe2df0f7515.webp</url>
<title>Geron Corporation</title>
<link>https://6ix.com/company/geron-corporation</link>
</image>
<item>
<title>Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026</title>
<link>https://6ix.com/company/geron-corporation/news/geron-plans-to-announce-first-quarter-2026-financial-results-on-may-6-2026</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-plans-to-announce-first-quarter-2026-financial-results-on-may-6-2026</guid>
<pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its first quarter 2026 financial results and business highlights before the market opens on Wednesday, May 6, 2026 via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call and webcast</description>
</item>
<item>
<title>Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary</title>
<link>https://6ix.com/company/geron-corporation/news/geron-announces-appointment-of-timothy-williams-as-executive-vice-president-chief-legal-officer-and-corporate-secretary</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-announces-appointment-of-timothy-williams-as-executive-vice-president-chief-legal-officer-and-corporate-secretary</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies FOSTER CITY, Calif., April 13, 2026 (GLOBE</description>
</item>
<item>
<title>Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/geron-corporation/news/geron-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives</description>
</item>
<item>
<title>Geron Announces Appointment of New Members to its Board of Directors</title>
<link>https://6ix.com/company/geron-corporation/news/geron-announces-appointment-of-new-members-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-announces-appointment-of-new-members-to-its-board-of-directors</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies FOSTER</description>
</item>
<item>
<title>Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/geron-corporation/news/geron-corporation-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-corporation-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>Achieved $48 million and $184 million in RYTELO® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating</description>
</item>
<item>
<title>Geron Plans to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/geron-corporation/news/geron-plans-to-present-at-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-plans-to-present-at-upcoming-investor-conferences</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives</description>
</item>
<item>
<title>Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026</title>
<link>https://6ix.com/company/geron-corporation/news/geron-plans-announce-fourth-quarter-122700323</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-plans-announce-fourth-quarter-122700323</guid>
<pubDate>Wed, 11 Feb 2026 12:27:00 GMT</pubDate>
<description>FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its fourth quarter and full year 2025 financial results and business highlights before the market opens on Wednesday, February 25, 2026 via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conferen</description>
</item>
<item>
<title>Geron Corporation Provides 2026 Financial Guidance</title>
<link>https://6ix.com/company/geron-corporation/news/geron-corporation-provides-2026-financial-guidance-2026-01-12</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-corporation-provides-2026-financial-guidance-2026-01-12</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>2026 RYTELO® (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to</description>
</item>
<item>
<title>Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/geron-corporation/news/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-12</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-12</guid>
<pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that,</description>
</item>
<item>
<title>Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation</title>
<link>https://6ix.com/company/geron-corporation/news/geron-corporation-announces-strategic-restructuring-plan-position-company-long-term</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-corporation-announces-strategic-restructuring-plan-position-company-long-term</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER</description>
</item>
<item>
<title>Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS</title>
<link>https://6ix.com/company/geron-corporation/news/geron-corporation-presents-new-data-ash-2025-highlighting-relationship-between</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-corporation-presents-new-data-ash-2025-highlighting-relationship-between</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with</description>
</item>
<item>
<title>Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/geron-corporation/news/geron-corporation-reports-third-quarter-2025-financial-results-and-recent-business</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-corporation-reports-third-quarter-2025-financial-results-and-recent-business</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>Achieved $47.2 million in RYTELO® net product revenue in Q3 2025 Completed enrollment in Phase 3 IMpactMF clinical trial evaluating imetelstat in</description>
</item>
<item>
<title>Geron Corporation to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/geron-corporation/news/geron-corporation-present-upcoming-investor-conferences-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-corporation-present-upcoming-investor-conferences-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the</description>
</item>
<item>
<title>Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies</title>
<link>https://6ix.com/company/geron-corporation/news/geron-corporation-announces-five-presentations-selected-ash-2025-highlighting</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-corporation-announces-five-presentations-selected-ash-2025-highlighting</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores relationship between treatment-emergent cytopenias and</description>
</item>
<item>
<title>Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025</title>
<link>https://6ix.com/company/geron-corporation/news/geron-plans-announce-third-quarter-2025-financial-results-november-5-2025-2025-10-27</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-plans-announce-third-quarter-2025-financial-results-november-5-2025-2025-10-27</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company aiming to change lives by changing the</description>
</item>
<item>
<title>Cassava Sciences Appoints Dawn C. Bir to the Board of Directors</title>
<link>https://6ix.com/company/geron-corporation/news/cassava-sciences-appoints-dawn-c-bir-to-the-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/cassava-sciences-appoints-dawn-c-bir-to-the-board-of-directors</guid>
<pubDate>Wed, 22 Oct 2025 12:00:00 GMT</pubDate>
<description>AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the suc</description>
</item>
<item>
<title>Geron Corporation Announces Executive Leadership Transitions and Appointments</title>
<link>https://6ix.com/company/geron-corporation/news/geron-corporation-announces-executive-leadership-transitions-and-appointments-2025-10</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-corporation-announces-executive-leadership-transitions-and-appointments-2025-10</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE</description>
</item>
<item>
<title>Geron to Participate in the 2025 Wells Fargo Healthcare Conference</title>
<link>https://6ix.com/company/geron-corporation/news/geron-participate-2025-wells-fargo-healthcare-conference-2025-08-27</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-participate-2025-wells-fargo-healthcare-conference-2025-08-27</guid>
<pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that management is</description>
</item>
<item>
<title>SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors</title>
<link>https://6ix.com/company/geron-corporation/news/spyglass-pharma-appoints-elizabeth-ofarrell-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/spyglass-pharma-appoints-elizabeth-ofarrell-to-its-board-of-directors</guid>
<pubDate>Tue, 19 Aug 2025 12:00:00 GMT</pubDate>
<description>ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O’Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O’Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. “Liz’s established track record in large, commerci</description>
</item>
<item>
<title>Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/geron-corporation/news/geron-corporation-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2025-08</link>
<guid isPermaLink="true">https://6ix.com/company/geron-corporation/news/geron-corporation-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2025-08</guid>
<pubDate>Fri, 08 Aug 2025 04:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an</description>
</item>
</channel>
</rss>